Replies to post #85847 on Biotech Values

[DewDiligence]

ITMN:

…I believe what we call "IPF" is actually multiple diseases, in which case it is likely that different drugs will work for different endpoints. I think there is a good chance in many of these trials that a fair number of patients have some completely different underlying condition. "True" IPF is supposed to be rapidly progressive and fatal within a few years - that's not always what we have seen in the placebo groups in IPF trials. We really need some biomarkers to figure out the different subgroups.

An interesting observation. Let me rephrase ghmm’s question on the relevance to ITMN of the pending Tracleer results in IPF. Which of the following most closely conveys your opinion?

a) Tracleer’s success in IPF is strongly bullish for ITMN.
b) Tracleer’s success in IPF is modestly bullish for ITMN.
c) Tracleer’s success in IPF is strongly bearish for ITMN.
d) Tracleer’s success in IPF is modestly bearish for ITMN.
e) Tracleer’s results in IPF have no bearing on ITMN one way or the other.

T.i.a. Dew